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Abstract: Transplantation has made a considerable difference to the lives of many patients. 
However, feedback from patients indicates that although having a transplant is a hugely posi-
tive experience, having to take medications indefinitely is one of the biggest challenges. An 
ideal scenario would be no medications following a transplant. A compromise would be a 
minimal number of medications, with minimal restrictions and as simple a regimen as possible. 
Although there is considerable research going into fine-tuning the management of the immune 
response to a transplant, to date there is no universal regimen that enables patients to remain 
free of immunosuppressant medications, making adherence paramount to maintain long-term 
allograft survival. This paper reviews the available immunosuppressant regimens and factors 
influencing choice from both the clinician’s and the patient’s perspective. Factors influencing 
the decision-making process, such as quality of life for patients, their satisfaction, acceptability, 
and adherence uptake are reviewed. We conclude with a further assessment of patient choice 
as a factor in regimen selection, its impact on adherence, and its implications. 
Keywords: adherence, transplant, allograft, immunosuppressants, patient involvement, satis-
faction, decision-making
Introduction
Successful kidney transplantation is life-changing for those with organ failure. In the 
case of the heart, lungs, and liver, it is life-saving, as there are no long-term artificial 
replacements for these organs. Transplantation frees those with or approaching end-
stage renal failure from the impositions of restricted fluid intake, strict nutritional 
regimens, and the potential need for dialysis to a state of independence. Where an 
individual is a suitable candidate for a renal transplant, it provides them with a new 
lease of life and the ability to achieve near-normal kidney function, and freedom from 
attachment to machines and the significant time commitment of the actual process of 
performing the dialysis. In those requiring a pancreas transplant, it could mean freedom 
from repeated insulin injections, glucose monitoring, and dangerous hypoglycemic 
episodes, along with potential reversal of some of their diabetic complications. 
It would of course be wrong to assume that transplantation is without its own atten-
dant problems. Only patients fit enough to undergo major surgery can be transplanted. 
They also need to receive an appropriately matched organ in order to prevent loss of 
the transplant. The bane of the transplant recipient (patient) is the absolute necessity 
of continuous, appropriately timed, regular use of immunosuppression. Although 
matching across immunological barriers enables less immunosuppression in the 
peri-transplant period, some degree of immunosuppression is consistently necessary. 
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The breakdown of this could lead to rejection, toxic dam-
age to the transplant, and/or potential compromise to the 
recipient’s health. 
It is becoming vanishingly rare to lose transplanted organs 
in the first year in the absence of surgical or unsuspected 
immunological problems. Surgical techniques continue to 
improve and become more refined, and in addition, our 
understanding of the immunobiology around rejection is 
expanding. The long-term success of organs nowadays is 
dependent on appropriate long-term follow-up by individu-
als in a team with expertise and experience in the long-term 
management of post-transplant care. In the early days of 
transplantation, the surgeon who did the operation often led 
the post-transplant care. However, this care has evolved over 
time to encompass a multidisciplinary team that involves not 
only the transplanting surgeons but also transplant physicians 
with immunology training, specialist nurses, pharmacists to 
monitor adherence and drug interactions, dietitians to advise 
on changing diet, and psychologists and social workers to 
support individuals through the process. Additionally, the 
support of laboratory staff for chemistry, hematology, and 
immunology monitoring is required. Varying renal func-
tion and other chemistry, the immunosuppression used to 
overcome the natural immune response leading to issues 
around side effects and drug interactions, and the psychologi-
cal and social impact of the process of receiving a foreign 
organ or tissue render the care of transplant recipients very 
complex. 
Nonadherence is emerging as a major cause of transplant 
loss. It is an area that is not fully understood as, in many cases, 
there is no clear indication of the reason. It is also difficult 
to accurately assess, and tools are constantly being reviewed 
to try and aid assessment. At present this is either by direct 
methods, which can involve direct observation of patients 
taking medications or measurement of drug concentrations in 
blood or urine, or indirect methods. Indirect methods include 
physician estimation, diary methods, patient interviews, 
questionnaires, pill counts, and electronic monitoring. 
Review of available regimens and 
factors affecting choice of regimen
Immunosuppression regimens for solid organ transplants are 
broadly divided into induction and maintenance regimens. 
The induction treatment consists of high-dose, more potent 
immunosuppressors in order to prevent the recipient’s 
immune system rejecting the newly grafted organ immedi-
ately due to the sudden challenge to the immune system in 
the early transplant period. 
The first attempts at immunosuppression used total 
body irradiation. Azathioprine was developed in 1957 and 
introduced by Sir Roy Calne in the 1960s, and accompa-
nied by steroids. The addition of induction therapy using 
anti-thymocyte globulin or anti-lymphocyte globulin was 
introduced in the 1970s, giving about 50% 1-year graft 
survival. The success of transplantation changed radically 
with the introduction of ciclosporin, the first calcineurin 
inhibitor, in the 1980s. Indeed, 1-year transplant survival 
went from 40%–50% to more than 80%, with a significant 
reduction in mortality.1
The immunosuppressant protocols in most centers con-
sisted almost uniformly of polyclonal antibody induction (or 
no induction antibody) and then maintenance immunosup-
pression with ciclosporin, azathioprine, and prednisolone. 
Development of new agents was driven by a desire to reduce 
side effects, such as infections and malignancy, as a result of 
excessive immunosuppression. Additionally, problems such 
as renal impairment, particularly noted in heart transplants 
where cardiac recipients often went on to require a kidney 
transplant. 
Subsequent developments have included tacrolimus, a 
calcineurin inhibitor first shown to be associated with less 
rejection in liver transplants. Mycophenolate mofetil, a newer 
and more potent antiproliferative agent, is now frequently 
used in place of azathioprine. Sirolimus, an mTOR (mam-
malian target of rapamycin) inhibitor was introduced in 
1999. It is currently used most commonly in patients unable 
to tolerate tacrolimus, but also increasingly in patients who 
have developed or who are at high risk of cancers. Induc-
tion therapy with biologic immunosuppressive agents has 
also broadened to include monoclonal antibodies to the IL-2 
receptor, eg, basiliximab. 
Development of additional immunosuppressant agents in 
the 1990s led to diversification of protocols. North America 
continued to favor the use of polyclonal antibodies for 
induction, while Europe was relatively prompt to switch to 
monoclonal antibody induction. 
In the current decade, several of the North American 
centers have switched to using monoclonal antibod-
ies for induction, including alemtuzumab (a humanized 
monoclonal antibody to CD52), mainly because of the 
increased incidence of lymphoma with anti-thymocyte 
and anti-lymphocyte globulin, particularly post-transplant 
lymphoproliferative disease. There have also been multiple 
studies showing equal efficacy with a relatively simpler 
regimen in relation to administration and a lower side 
effect profile.2,3 
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The more recent additions include costimulatory block-
ade, which was designed as a result of elegant research into 
understanding the signaling pathways involved in the T and B 
lymphocyte response.1 It was believed that adopting this 
approach would streamline the required immune suppression, 
thereby reducing other toxic side effects. Adoption of these 
agents has been variable, primarily due to the financial cost 
involved. Belatacept is a fusion protein containing a modified 
CD152 (CTLA-4) domain and a human IgG domain, which 
binds to the natural ligands for CD28, CD80, and CD86 
molecules crucial for T lymphocyte costimulation. It was 
designed to provide prolonged graft survival while limiting 
the toxicity caused by calcineurin inhibitor-based regimens. 
It has the additional potential benefit of assisting adherence 
and is administered as a monthly intravenous infusion, with 
subcutaneous preparations that could be administered by 
patients themselves in development. Trials have shown better 
preservation of renal function than with calcineurin inhibitor-
based regimens and a possible reduction in the development 
of donor-specific antibody, but this comes at the expense of 
a higher rate of episodes of rejection. 
The increased range of immunosuppressive drugs now 
available has provided the opportunity for individualized 
agent choice and drug dosing. These include steroid avoid-
ance or early steroid withdrawal, and similarly, calcineurin 
inhibitor minimization or withdrawal. More recently, some 
clinicians have adopted strategies of calcineurin inhibitor 
avoidance, with variable outcomes. 
The majority of centers now aim to use dual therapy for 
longer-term graft maintenance. Commonly, this comprises 
the combination of a calcineurin inhibitor and an antiprolifer-
ative agent or low-dose steroids. In patients with malignancy 
or calcineurin inhibitor-related renal damage, calcineurin 
inhibitors replacement with mTOR inhibitors (sirolimus or 
everolimus) is increasingly being adopted. A few centers 
have been trialing long-term use of a single immunosuppres-
sant agent. This is being achieved by using alemtuzumab, the 
costimulatory monoclonal antibody directed against CD52, 
which depletes both T and B lymphocytes.4
The increasing choices in immunosuppressant medica-
tions has led to considerable diversification in regimens 
used around the world, intercenter and indeed in some cases 
intracenter. This has the potential for making direct compari-
son of outcome data a challenge, and this is particularly an 
issue for randomized trials because they will never be able 
to compare all the available options. There remains a clear 
need for more effective, easily administered, and less toxic 
immunosuppressive drugs. 
Efficacy studies including 
comparative safety, and 
tolerability studies
The advent of calcineurin inhibition (ciclosporin and later tac-
rolimus) was the major breakthrough in enabling successful 
transplantation. Unfortunately, these agents have attendant 
side effects, such as hypertension, toxicity to the grafts, dia-
betes, malignancy, and neurological adverse events. Studies 
looking at minimization of calcineurin inhibition, withdrawal, 
and avoidance protocols, particularly after kidney transplants, 
have had variable results. 
More recently, the role of pharmacogenetics in early and 
appropriate dosing of calcineurin inhibitors for transplant 
recipients has been investigated. The most widely explored 
and the nearest gene to introduction into routine clinical 
practice to assist tacrolimus dosing is cytochrome P450 3A5 
genotype.5,6 
Attempts at reducing the side effect profile have led to 
various strategies in new protocols. With good short-term 
outcomes, effort has been concentrated on developing 
protocols to minimize toxicity and improve long-term graft 
survival. One of the most influential studies recently has been 
the SYMPHONY study, which has led to the widespread 
adoption of an immunosuppressive regimen based on low-
dose tacrolimus, mycophenolate mofetil, and steroids with 
or without use of an anti-interleukin-2 receptor antibody for 
induction.3
Importance of adherence  
to long-term transplant outcomes
It is not surprising that poor adherence to immunosuppressive 
drug treatment is associated with a poor transplant outcome. 
In a meta-analysis of ten studies, nonadherence was found 
to increase the risk of graft failure by seven-fold when com-
pared with adherent patients.7 Recently published data on the 
cause of renal transplant failure have indicated the key role 
of chronic antibody-mediated rejection associated with poor 
adherence to treatment.1 This has moved adherence up the 
agenda of aspects of transplant care that may be amenable to 
intervention to improve long-term transplant survival.
Patient-focused perspectives: quality 
of life, satisfaction/acceptability, 
adherence, and uptake
The health belief model offers a possible explanation for why 
transplant recipients adhere or not to immunosuppressant 
medications. The health belief model is a psychological health 
behavior change model, which was originally developed to help 
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explain and predict the health-related behavior of patients in 
relation to uptake of health services in general. It suggests that 
individuals will take action to manage disease, such as adhering 
to medications, if they: perceive themselves as susceptible to 
a disease; believe the disease to have serious consequences; 
and believe the benefits of taking action to manage the disease 
outweigh the barriers to or costs of the action.8 
The model suggests that the likelihood of taking action 
is affected by perceived barriers to action, perceived benefits 
of action, external influences that may cue action, and other 
variables, such as demographics, psychosocial factors, once-
daily dosing versus multiple daily doses, side effect profile, 
and cost for those patients who pay for their medications.8,9 
Men, older patients, single young adults, and patients 
who have had transplants for a long time are traditionally 
described as being likely to be more nonadherent than 
others,9,10 although this has been called into question by other 
researchers in meta-analysis.11 Estimating the true degree of 
nonadherence among transplant recipients is not easy given 
that it often only becomes recognized after a measurable 
event. There is, however, also a significant proportion of 
patients who have subclinical nonadherence.
Most patients who do not adhere report forgetting doses, 
missing doses, being careless about doses, but less commonly 
report stopping immunosuppressant medications altogether 
for periods at a time and even more rarely stopping them 
altogether. Problems that are a direct result of nonadherence 
to immunosuppressant medications include graft rejection, 
decreased quality of life, increased health care costs, need 
for dialysis, morbidity, and mortality.6
It therefore becomes important to identify areas where 
health care professionals can potentially have a signifi-
cant impact on adherence in their transplant recipients. 
Nonadherent organ recipients perceive greater barriers 
to medication adherence, are less likely to believe that 
their immunosuppressant medications are necessary, and 
are more likely to have concerns regarding them. In our 
anecdotal experience, a recent issue that has led to patients 
believing that they do not need immunosuppressive drugs 
is the publication of data on a small cohort of immunologi-
cally tolerant transplant patients who stopped immunosup-
pressive treatment and have preserved graft function.12 
Unfortunately, the nonexpert reader may not be able to put 
these data into an appropriate perspective and arrive at an 
erroneous conclusion. 
Nonadherent recipients also have a tendency to report 
lower life satisfaction than adherent recipients. Thus, 
strategies for eliminating barriers to adherence, as well 
as identifying and alleviating patient concerns about 
immunosuppressant medications, are potentially promising 
areas of focus for future adherence programs. By imple-
menting successful adherence interventions, health care 
professionals may be able to enhance not only adherence of 
transplant patients to essential immunosuppressant medica-
tions, but also their health status and life satisfaction, a key 
factor associated with quality of life.13
Patient choice as a factor in regimen 
selection and impact on adherence
Involving patients in health care decisions can make a 
potentially significant and enduring difference to health 
care outcomes.14–16 The ethical need for patient choice, 
respecting autonomy, and responding to patients’ demands 
for more involvement in their treatment is becoming widely 
recognized.17–19
Pharmaceutical interventions offer well documented 
benefits at the population level. However, for the individual 
patient, the immediate clinical effect may be side effects, 
whereas benefits may not be possible to identify or measure 
directly.20 This is why patient choice can have a significant 
impact on adherence. 
Advances in immunosuppressant medications have 
resulted in notable improvements in post-transplant out-
comes, particularly in the first year. However, longer-term 
outcomes have not improved to the same extent.21 One of the 
major factors contributing to the incidence of late acute rejec-
tion and graft loss in transplant patients is nonadherence.22 
The prevalence of nonadherence to medication following 
kidney transplantation has been reported to be in the order 
of 15%–55%.7,23 
It is now understood that problems with adherence can 
affect all transplant recipients and are not limited to tradi-
tional “risk groups”, such as the elderly and adolescents. In a 
large meta-analysis including studies of kidney, heart, liver, 
and pancreas transplants, nonadherence was not shown to be 
associated with sex, age, ethnicity, or level of education.11 
There can be many other confounding factors in the study of 
adherence, such as age, income, time since transplant, and 
form of immunosuppressant prescribed.24 Post-transplant 
nonadherence is increasingly regarded as a preventable 
cause of late acute rejection, chronic rejection, and graft 
loss.7,22 Since medication adherence is usually not predict-
able, emphasis should be placed on increasing adherence in 
all patient groups.13,25
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Addressing medication nonadherence often requires a 
multifaceted approach, which includes developing methods 
of identifying nonadherence, models to identify determinants 
of and factors promoting nonadherence, and strategies to 
educate patients concerning their therapy. Finally, practical 
interventions by multidisciplinary practitioners need to be 
adopted.26 
Shared decision-making allowing patient choice, as 
opposed to clinicians merely making decisions on behalf 
of patients, is gaining increasing prominence in health care 
policy.27–30 Shared decision-making has been defined as:
An approach where clinicians and patients share the best 
available evidence when faced with the task of making 
decisions, and where patients are supported to consider 
options, to achieve informed preferences.14
This approach may be beneficial in managing adherence 
to immunosuppressive regimens. 
Effective communication can enhance knowledge, 
involvement in decisions about interventions, autonomy, and 
empowerment of patients.20 In contrast, poor communica-
tion can lead to anxiety, lack of confidence in the clinician, 
and to decisions based on misinterpreted information and 
inadequate communication.31 The prescriber should try to 
understand the health beliefs and expectations of the patient 
regarding their treatment. Adherence to therapy is more likely 
if the patient understands the reason for taking a drug and is 
involved in the decision to prescribe. Patients are more likely 
to have confidence in the prescriber if given basic knowledge 
of potential adverse effects and advice on what to do if they 
occur. They should be made aware of how to take the drug 
and for how long they will need to take it.32
Shared decision-making is supported by evidence from 
86 randomized trials showing knowledge gained by patients, 
more confidence in decisions, more active patient involve-
ment, and in many situations, informed patients elect for 
more conservative treatment options.33 However, the trend 
to allow more patient choice has led to concern regarding 
potential “abandonment”, where clinicians offer information 
about treatment choice but no guidance.34 Indeed, doubts have 
been expressed by some health care professionals, suggesting 
that patients do not want to be involved in decisions, lack 
capacity or ability, might make “bad” decisions, or worry 
that shared decision-making is not practical, given constraints 
such as time pressure. 
Others claim that shared decision making is already in 
place, but data from patient experience surveys indicate that 
this is not generally the case.35,36 Therefore, it is essential that 
in order to advocate the uptake of shared decision-making, 
both clinicians and patients need to support the underlying 
rationale. There are a number of challenges that clinicians 
will face. These include low health literacy or low numeracy, 
in addition to cultural backgrounds that may lack a tradition 
of individuals making autonomous decisions. It is prudent 
that the shared decision-making process is built on core skills 
of good clinical communication, with building a rapport and 
structured consultations.37
Shared decision-making involves three key steps, ie, 
“choice talk”, “option talk”, and “decision talk”, where 
the clinician supports deliberation throughout the process. 
Choice talk refers to the step of making sure that the patient 
knows that reasonable options are available. Option talk 
refers to providing more detailed information about options, 
and decision talk refers to supporting the work of considering 
preferences and deciding on the best option.38 
“Paternalism” has acquired a negative connotation in 
medicine, but has an inevitable role in the prescription of 
treatments with a complex basis. Ultimately, the complexity 
of decision-making around immunosuppressive treatment 
will challenge many patients with a need for substantial 
support based on the clinician’s interpretation of the risks 
and benefits of treatment.
Patients will need time to interpret the information given to 
them and to consider personal preferences, particularly where 
outcome states are unknown. Deliberation may, in part, be done 
outside the clinical encounter, although patients often wish to 
consolidate their views with a clinician.38 Patients will want to 
discuss options with others, and Rapley has referred to this need 
as a “distributed deliberation process”.39 Recognizing this need 
and allowing time for it is a cornerstone for effective shared 
decision-making. Decision support interventions, which sum-
marize information in formats that are accessible to patients, 
using the most up-to-date evidence about harms and benefits can 
also be used.40 These can be in concise formats, such as in brief 
text or diagrams, or can be extensive, as in booklets, websites, 
videos, and DVD, to be used by patients, their friends, and their 
families during and outside the clinic consultations.38
In summary, shared decision-making, enabling patient 
choice, may enhance adherence to immunosuppressive 
regimens. Clinicians need to be respectful and remain alert 
to the patient’s individual preferences. Although challenges 
exist, the benefits of patient choice and involvement, and 
the skills required to achieve this approach, need to be given 
much higher priority. 
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Impact of choice of 
immunosuppressive drug regimen
The drugs in widespread use for immunosuppressive treat-
ment in transplant recipients have all now come off patent, 
with the recent availability of generic preparations at vastly 
reduced cost compared with the innovator products. In 
health care systems where the patient has to buy their own 
medication, use of cheaper generic products may have a 
major impact on adherence. It is of note that the reported 
incidence of nonadherence in renal transplant recipients is 
much higher in the USA, where state provision of immuno-
suppressive treatment is limited to 3 years (currently under 
review) than in health care systems such as the UK and 
Canada which have long-term state provision of treatment.41 
There is major pressure from state and insurance funders to 
use generic rather than innovator immunosuppressive agents 
to save money. Any patient being changed from treatment 
with an innovator to a generic drug ought to be involved 
in the decision-making process in order to maintain trust. 
There tends to be understandable suspicion, which can be 
overcome by provision of evidence of equivalence, and it is 
important that clinicians are transparent as to the underlying 
reason for change. This is a situation where the wishes of 
the individual patient may be in conflict with the needs of the 
health care system. The decision-making process therefore 
goes beyond just the patient and their health care providers 
in a state-funded health care system; for instance, in the UK, 
the regulatory body National Institute for Health and Care 
Excellence.42
There are some data indicating a very small but statisti-
cally significant increase in adherence by patients treated with 
once-daily rather than twice-daily tacrolimus.43,44 Patients 
who maintain the number of skipped doses after conversion 
from twice-daily to once-daily dosing might be better served 
by a twice-daily regimen.44 A potential barrier to this option is 
the increased cost of the once-daily preparation, where there 
is no generic option, which may actually impact negatively 
on adherence in health care systems where patients need to 
buy their own medications.
Conclusion and implications
It is clear that while transplantation can be life-saving or 
life-enhancing, maintaining the organ can be a challenge as 
a result of the necessity for lifelong immunosuppressants. 
Current knowledge and medicine do not allow for indefinite 
survival of grafts without long-term immunosuppression. In 
view of this, the clinician requires a broad knowledge and 
appropriate skills in the management of immunosuppression 
in order to enhance adherence and minimize side effects in 
the individual patient by tailoring their medication according 
to lifestyle, comorbidities, and immune status. It is clear that 
patient engagement is needed to achieve optimal adherence 
and ultimately maximal graft survival. Early identification 
of potential barriers and promoters of adherence is needed 
in the run-up to transplantation as well as in the follow-up 
period after transplant. In some instances, this may require 
a skill mix beyond the reach of the nurse, pharmacist, physi-
cian, or surgeon (see Table 1). 
Adherence may be achieved as a result of guilt (eg, 
wanting to please family or the medical team), concern at 
being judged/marginalized although it is best sustained when 
self-motivated. Early identification of potential problems in 
relation to a patient’s status and support network could have 
a significant influence on adherence. Understanding of the 
dynamics of a patient’s social network can prove invaluable 
and could lead to identification of a couple of buddies for the 
organ recipient to support them through the process. Issues 
with forgetting medications, confusion around taking medi-
cines at different times of the day, timing with food, and dif-
ficulty following instructions can often be circumvented with 
appropriate aids and techniques, such as alarms, drug cards, 
dosette boxes, and individualized education sessions. 
In contrast, patients skipping medications to avoid side 
effects require an astute, supportive clinician and pharmacy 
involvement. Cycles of breakdown in adherence due to 
patients becoming fed up with regimens may require a major 
pattern change and input from a psychologist to work through 
precipitating factors and to develop motivating and alterna-
tive behavioral strategies. Beyond psychology input, psychi-
atric input may be required, and recognizing this requirement 
early is paramount, given that depression is commonly seen 
in patients with chronic disease and frequently presents as 
nonadherence. It is noteworthy that cries for help and suicide 
can also be played out through nonadherence.
It is becoming increasingly clear that organ transplanta-
tion goes beyond performing an operation and handing out 
pills. It is fair to say that solving adherence problems and 
developing solutions warrants focused research. There have 
been amazing breakthroughs achieved in complex surgical 
techniques in the past century. There is now scientific and 
medical understanding to overcome even the most challeng-
ing of immunological barriers to enable acceptance and func-
tion of a transplanted organ. Nonadherence is emerging as a 
major factor leading to graft loss. It should be viewed as a 
potentially modifiable factor influencing graft survival. How-
ever, ultimately, long-term survival of a transplant requires 
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Table 1 Barriers, causes, and calls to action to improve adherence
Potential 
adherence barriers
Potential causes of 
adherence barriers
Calls to action to overcome adherence barriers
Medical Side effects 
Drug interactions
Pill burden
Involvement of pharmaceutical companies in modification of current 
medications and development of new ones to reduce side effects 
and interactions
involvement of pharmacists and specialist nurses as well as physicians 
to identify patients with side effects and potential drug interactions
Careful monitoring of drug levels to avoid toxic side effects or problems due 
to inadequate dosing 
Dietitian involvement to ensure appropriate medication delivery 
and to ensure a healthy diet with only necessary restrictions
Regular review of entire patient prescriptions to rationalize pill burden
Ongoing liaison with community doctors and pharmacists 
Social Peer pressure
Restriction by work, social life
Disruption of routines, eg, job 
loss, moving house, divorce, 
transitioning to new units or 
from pediatric to adult units 
Create awareness of transplantation and immunosuppression adherence 
in society through educational sessions, social media, and television
Development of buddy programs to convert peer pressure 
to positive support
Develop supportive pathways for seamless transition of young adults from 
pediatric to adult services
Social worker involvement
Psychology services
emotional and mental Depression
Mood swings
Psychosis
Early identification of symptoms in patients
Identification and involvement of patient’s network (next of kin, family, 
friends) where appropriate 
integrated support from psychologists and/or psychiatrists depending 
on diagnosis 
educational illiteracy
Complex regimens
Development of clear educational strategies to suit the patient’s  
educational level 
early recognition of patients who may struggle, ideally in the pre-transplant 
period
Use of dosette boxes, blister packs, direct observation, alarms, and drug cards
Simplification of the immunosuppressant regimens, eg, use of once daily 
regimens 
Tailoring regimens to suit patient’s lifestyle 
Financial Cost of immunosuppressant 
medications
Call to pharmaceutical companies to rationalize prices with potential 
discounts for developing countries
Use of properly tested generics to create a competitive market
Government legislation to ensure support for immunosuppressant regimen 
cost for patients without adequate insurance, subsidizing or covering cost 
for the life of the transplant 
Create awareness in patients about prioritization of their immunosuppressants 
in situations of limited finances
input from social workers 
Note: The information in this table is not exhaustive but rather seeks to compartmentalize some of the potential barriers to adherence and offer potential solutions.
the uncompromised input of the patient, their support net-
work, and the entire multidisciplinary clinical team.
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